Sign inJoin waitlistJoin the waitlist

James Blachly

Assistant Professor · Ohio State University Hospital

Credentials: · · · · · ·

History

Ohio State University Hospital
Present
Ohio State University Hospital
Present

Hematology and Medical Oncology
Ohio State University-Main Campus
2010–2013
Internal Medicine
Ohio State University Hospital
2007–2010
Univ of Arkansas Coll of Med
2003–2007

Research

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
New England Journal of Medicine · 2018 · 782 citations
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Journal of Clinical Oncology · 2017 · 431 citations
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology · 2025 · 213 citations

JB
John Byrd
74 papers
Alice Mims
30 papers
Richard Stone
30 papers
JK
Jonathan Kolitz
27 papers
Bayard Powell
25 papers
Gerard Lozanski
24 papers
KR
Kerry Rogers
23 papers
MG
Michael Grever
23 papers
CB
Clara Bloomfield
22 papers
Jennifer Woyach
20 papers
Bhavana Bhatnagar
19 papers
KL
Karilyn Larkin
19 papers · 1 as a fellow

Clinical trials

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2019–2022
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
Principal investigator · Withdrawn · Phase 2
James Blachly
2015
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Site PI · Recruiting · Phase 1, Phase 2
Syndax Pharmaceuticals
2019–2027